

*許朝偉醫師

所有發表期刊論文

1. **Hsu CW**, Yeh CT*, Chen PG, Liaw YF. Replication of hepatitis C virus in ascitis mononuclear cells with development of distinct virus quasispecies. *J Infect Dis* 1999;180:992-1000.
2. **Hsu CW**, Lin CJ*, Jeng LB, Tseng JH, Chen TC. Adenosquamous carcinoma of the duodenum presented with obstructive jaundice: report of a case. *Gastroenterol J Taiwan* 2000;17:8-14.
3. **Hsu CW***, Sheen IS, Chu CM. The pathophysiology, diagnosis and treatment of hepatitis C. *Medicine Update, CGMH* 2002;4(4):52-59.
4. Lin CH, **Hsu CW***, Chiang YJ, Ng KF, Chiu CT. Esophageal and gastric Kaposi's sarcoma presenting as upper gastrointestinal bleeding. *Chang Gung Med J* 2002;25:329-333.
5. Lin SM*, Shen CH, Lin DY, Kuo SH, Lin CJ, **Hsu CW**, Chung HJ, Peng CY. Cytologic changes in small hepatocellular carcinomas after radiofrequency ablation. *Acta Cytol* 2002;46:490-494.
6. Lin C, **Hsu CW***, Tseng JH, Huang SF, Chen PC. Colonic actinomycosis presenting as diffuse colitis and protein-losing enteropathy: a case report. *Gastrointest Endosc* 2003;58:448-451.
7. Lin SM*, Lin CJ, Chung HJ, **Hsu CW**, Peng CY. Power roll off during interactive radiofrequency ablation can enhance necrosis when treating hepatocellular carcinoma. *AJR* 2003;180:151-157.
8. Lin SM*, Lin CJ, **Hsu CW**, Tai DI, Sheen IS, Lin DI, Liaw YF. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. *Cancer (Cancer Cytopathol)* 2004;100:376-382.
9. Lin SM*, Lin CJ, Lin CC, **Hsu CW**, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤ 4 cm. *Gastroenterology* 2004;127:1714-1723.
10. Yu LK, **Hsu CW***, Tseng JH, Liu NJ, Sheen IS. Splenic infarction complicated with splenic artery occlusion following histoacryl injection for gastric varices: a case report. *Gastrointest Endosc* 2005;61:343-345.
11. Lin SM*, Lin CJ, Lin CC, **Hsu CW**, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3cm or less. *Gut* 2005;54:1151-6.
12. **Hsu CW***, Lin DI. Problem-Based Learning Tutor Guide: Drug induced liver disease. Chang Gung University, 教案編號: I-GI 003, 2006 Mar.
13. Yeh CT*, Lin WP, **Hsu CW**, Chang ML, Lin SM, Sheen IS. Emergence and takeover of precore-stop mutant prior to exacerbation of e antigen-negative chronic hepatitis B after withdrawal of lamivudine therapy. *J Med Virol*. 2006; 78:906-910.
14. Yeh CT*, **Hsu CW**, Chang ML, Sheen IS, Lin SM, Lin CJ, Lin CC, Chen YC, Chen JC. A novel ex vivo assay of interferon-based suppression, to predict the outcome of antiviral therapy for

- hepatitis C. *J Infect Dis.* 2006;193:1365-70.
15. **Hsu CW**, Cheng JC, Yeh CT*. Quantitative assessment of serum NV-F virus DNA concentrations in samples from patients coinfecting with hepatitis B or C virus. *J Clin Microbiol* 2006;44:3130-3133.
 16. **Hsu CW**, Yeh CT*, Chang ML, Liaw YF. Identification of a mutation hot spot in the S Gene in patients experiencing HBsAg seroclearance after lamivudine therapy. *APASL*, 2006,3-5
 17. Sheen IS, Tsou YK, Lin SM, Lin CJ, Lin CC, **Hsu CW**, Chen YC, Chang ML, Yeh CT*. Nuclear HBcAg and histology activity index as independent predictors the expression of singly spliced HBV-RNA. *J Viral Hepat.* 2007;14:70-74.
 18. Yeh CT*, Chen TC, Chang ML, **Hsu CW**, Yeh TS, Lee WC, Huang SF, Tsai CC. Identification of NV-F virus DNA in hepatocellular carcinoma. *J Med Virol.* 2007;79:92-96.
 19. **Hsu CW**, Yeh CT*, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing seroclearance. *Gastroenterology*, 2007;132:543-550.
 20. Lin CY*, Tsai MC, Huang CT, **Hsu CW**, Tseng SC, Tsai IF, Chen YC, Yeh CT, Sheen IS, Chien RN. Liver injury is associated with enhanced regulatory T-cell activity in patients with chronic hepatitis B. *J Viral Hepat.* 2007;14:503-11.
 21. Lin SM*, Lin CC, Chen WT, Chen YC, **Hsu CW**. Radiofrequency ablation for hepatocellular carcinoma: a prospective comparison of four radiofrequency devices. *J Vasc Interv Radiol.* 2007;18:1118-25.
 22. Lai CL*, Gane E, Liaw YF, **Hsu CW**, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Fielman B, R.N., and Brown NA. Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. *N Engl J Med* 2007;357:2576-88.
 23. Cua IHY, Lin CC, Lin CJ, Chen WT, **Hsu CW**, Chen YC, Wong SN, Lin SM*. Treatment of hepatocellular carcinoma using internally cooled electrodes. A prospective comparison of modified automated vs. manual pulsed radiofrequency algorithms. *Oncology.* 2007;72 :76-82.
 24. Chen WT, Lin SM*, Lin CJ, Lin CC, **Hsu CW**, Chen YC. Pneumoperitoneum following percutaneous radiofrequency ablation of hepatocellular carcinoma unrelated to bowel injury: a case report. *Hepatogastroenterology.* 2007;54(80):2365-7.
 25. Yeh CT*, Tang JH, **Hsu CW**, Chen YC, Chang ML, Lin CY. Expression of hepatitis B virus nuclear core antigen in young cirrhotic patients is associated with an unfavourable long-term outcome. *J Viral Hepat.* 2008 Nov;15(11):839-48.
 26. Lin CC, Lin CJ, **Hsu CW**, Chen YC, Chen WT, Lin SM*. Fine-needle aspiration cytology to distinguish dysplasia from hepatocellular carcinoma with different grades. *J Gastroenterol Hepatol.* 2008;23:e146-52.
 27. Hsieh YY, **Hsu CW***, Kuo TT, Yeh CT, Lin SM, Lin DY. Cutaneous Metastasis from Hepatocellular Carcinoma: Report of a Case. *Gastroenterol J Taiwan.* 2008; 25(3):249-54.
 28. Chang ML, **Hsu CW**, Huang SF, Chen TC, Lin SM, Yeh CT*. Dense packing of portal lymphocytes

predicts favorable treatment outcome in hepatitis C. *Hepatogastroenterology*. 2008;55(86-87):1716-20.

29. Yeh CT*, **Hsu CW**, Chang ML, Tsao ML. Impact of the novel hepatotropic viruslike agent NV-F during chronic hepatitis C virus infection. *J Infect Dis*. 2008;198(12):1742-8.
30. **Hsu CW**, Yeh CT*, Chen YC, Liaw YF. Lamivudine withdrawal in chronic hepatitis B patients after achieving effective maintained virologic suppression. *Hepatology* 2008;48(SUPPL):724A.
31. Leung N*, Peng CY, Hann HW, Sollano J, Lao-Tan J, **Hsu CW**, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. *Hepatology*. 2009;49(1):72-9.
32. **Hsu CW***, Chen YC, Liaw YF, Gane Edward, Manns Michael, Zeuzem Stefan, Wang Yuming, Lai CL, Hou JL, Leung Nancy, Bzowej Natalie, Niu Junqi, Jia JD, Hwang SG, Cakaloglu Yilmaz, Ren Hong, Papatheodoridis George, Chen Yagang, Bao Weibin, Lopez Patricia. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from globe and 015 studies in chronic hepatitis B patients. *J Hepatology*. 2009;50:S331.
33. Lai MW, Huang SF, **Hsu CW**, Chang MH, Liaw YF, Yeh CT*. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. *Antivir Ther* 2009;14(2):249-61.
34. Yeh CT*, **Hsu CW**, Chen YC, Liaw YF. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. *J Clin Virol*. 2009 Jun;45(2):114-8.
35. Chainuvati S*, Cheng J, Hou JL, **Hsu CW**, Jia JD, Komolmit P, Kwon SY, Lee CH, Li H, Li Y, Liu CJ, Neo BL, Peng CY, Tanwandee T, Wongcharatrawee S, Wu JC, Yu ML, Zhang XX. Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand. *Hepatol Int*. 2009 Jun 3:453-460
36. **Hsu CW***, Chen YC, Chao YC, Lee CM, Chang TT. Telbivudine 2303 Studies –Sub-analysis of Taiwan Patients. *Hepatol Int*. 2011;5(1):141.
37. Gane EJ*, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, Moon YM, Jia J, Chao YC, Niu J, Leung N, Samuel D, **Hsu CW**, Bao W, Lopez P, Avila C. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. *Liver int*. 2011;31(5):676-684.
38. **Hsu CW**, Yeh CT*. Emergence of hepatitis B virus S gene mutants in patients experiencing HBsAg seroconversion after peginterferon therapy. *Hepatology* 2011;54(1):101-8.
39. Yeh CT*, Chen T, **Hsu CW**, Chen YC, Lai MW, Liang KH, Chen TC. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. *BMC Cancer* 2011;11:398.
40. **Hsu CW**, Yeh CT*. Reply of HBV mutants associated with HBsAg loss: Chicken or egg ? to “Emergence of hepatitis B virus S gene mutants in patients experiencing HBsAg

seroconversion after peginterferon therapy". Hepatology Accepted manuscript online: 4 Oct 2011.

41. **Hsu CW***, Dai CY, Chen CH. When hepatology meet to rheumatology: chronic viral hepatitis and rheumatologic disease. Gastroenterol J Taiwan 2012;29:265-267.
42. Huang YH, Lin KH, Chen HC, Chang ML, **Hsu CW**, Lai MW, Chen TC, Lee WC, Tseng YH, Yeh CT*. Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PloS One 2012;7:e37188.
43. **Hsu CW***, Chao YC, Lee CM, Chang TT, Chen YC. Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24. BMC Gastroenterol. 2012 Dec 13;12:178
44. **Hsu CW**, Liang KH, Juang SF, Tsao KC, Yeh, CT*. Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores. BMC Res Notes. 2013 May 27;6:212
45. Jeng WJ, Sheen IS, Chen YC, **Hsu CW**, Chien RN, Chu CM, Liaw YF*. Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients. Hepatology. 2013;58(6):1888-96
46. Chen YC, **Hsu CW**, Chang MY, Yeh CT. * On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study. BMC Res Notes. 2013 Sep 2;6(1):349.
47. Lee CM, Chen CY, Chien RN, Tseng KC, Peng CY, Tung SY, Fang YJ, Huang YH, Lu SN, Hung CH, Tsai TJ, Fang CC, **Hsu CW**, Yeh CT. A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse. J Interferon Cytokine Res. 2013 Nov 15.
48. Yeh CT, Huang YH, Liang KH, Chang ML, **Hsu CW**, Chen YC, Chen TC, Yeh TS, Lee WC. Segregation of signaling proteins as prognostic predictors for local recurrence and distant metastasis in hepatocellular carcinoma. Int J Oncol. 2013 Nov 29.
49. Liang KH, Chen YC, **Hsu CW**, Chang ML, Yeh, CT. Decrease of serum Angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glomerular filtration rates. Hepat Mon. 2014 Jan 31;14(1):e15074. doi: 10.5812/hepatmon.15074. eCollection 2014
50. **Hsu CW**, Liang KH, Yeh CT. Inclusion of the quantitative hepatitis B surface antigen level establishes an effective non-invasive score for assessment of advanced liver cirrhosis. APASL 2014-3 annual meeting, Brisbane.

51. **Hsu CW**, Chao M, Chen YC, Chang ML, Huang SF, Yeh CT. Characterization of a naturally occurring replication-competent Defective interfering-like hepatitis D virus RNA lacking both ribozyme sites. EASL 2014-4 annual meeting, London.